Igea Pharma
Hoofddorp
About Igea Pharma
IGEA Pharma N.V. focuses on health-tech and med-tech products and devices. IGEA commercializes an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II prevention set in 2021.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $2.4M
- Funding stage: IPO
- Last round: Post-IPO Debt (Apr 2021)
- Ticker: swx:IGPH
- Website: igeapharma.nl
- Phone: +31 23 568 94 94
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/igea-pharma-2231028 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.